Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.
Sutro Biopharma (STRO) will host a conference call on Sept. 9, at 5:30 p.m. EDT to discuss updated data from ongoing Phase I dose escalation study of anti-Folate Receptor alpha (FRα) antibody-drug conjugate ((ADC)), STRO-002, in ovarian and endometrial cancer, with a data cut-off date of Aug. 31, 2020.Additionally, the company...
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data, being presented by Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., demonstrates STRO-002's immune-modulating properties and potentiation by PD-L1 blockade.
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that the company will present new preclinical data for its folate receptor alpha targeting antibody-drug conjugate, STRO-002, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020.